RESULTS: In AR-positive prostate cancer cell lines, overexpression of wild-type SgI considerably increased cell viability and migration in the presence of high levels (e.g. 100-300 mM) of zinc that was cytotoxic by itself. The wild-type SgI could also interact with AR and enhanced dihydrotestosterone-mediated AR transcription. By contrast, the mutant SgI failed to significantly increase cell proliferation/migration, to interact with AR, and to induce AR transactivation even in the presence of zinc. In addition, transfection of an 18-amino acid peptide of SgI containing LxxLL, but not LxxAA, resulted in significant inhibition of cell proliferation and PSA expression in LNCaP and C4-2 lines.
INTRODUCTION AND OBJECTIVES: BH3 mimetic drugs targeting BCL2 and/or BCLXL (navitoclax and venetoclax) have efficacy in hematological malignancies, but they do not block MCL1, and MCL1 expression may limit their effectiveness in solid tumors. The purpose of this study is to target apoptosis pathway in prostate cancer focusing on MCL1 inhibition in combined with BH3 mimetics.
METHODS: We conducted MCL1 knockdown with siRNA and shRNA and also generated MCL1 knockout prostate cancer cell line. In parallel studies, we screened in vitro a small series of drugs in combination with navitoclax to identify potentially effective combination therapies.
RESULTS: We initially found that MCL1 depletion markedly sensitized prostate cancer cells to navitoclax-mediated apoptosis in vitro and in vivo, indicating that they are primed to undergo apoptosis and protected by MCL1 and BCL2/BCLXL (figure 1). Small molecule EGFR kinase inhibitors (erlotinib, lapatinib) also dramatically sensitized to navitoclax-mediated apoptosis, and this was associated with markedly increased MCL1 degradation (figure 2). Significantly, this MCL1 degradation was not through GSK3b and downstream MCL1 ubiquitin ligases, and was not dependent on other known MCL1 ubiquitin ligases or deubiquitinases. Inhibitors targeting additional kinases (cabozantinib and sorafenib) similarly caused GSK3b-independent MCL1 degradation and synergized with navitoclax in vitro and in vivo.
CONCLUSIONS: These studies indicate that MCL1 stability is regulated by a novel mechanism downstream of receptor tyrosine kinase signaling in epithelial cancers, which may be exploited therapeutically.
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INTRODUCTION AND OBJECTIVES: Docetaxel-mediated chemotherapy is the first-line standard approach and has been determined to show a survival advantage for metastatic castration-resistant prostate cancer (mCRPC) patients. However, a substantial proportion of patients eventually becomes refractory due to drug resistance. The detailed mechanisms remain unclear. We have previously reported that Prostate Leucine Zipper (PrLZ), a specific oncogene of prostate cancer (PCa), promotes PCa cell growth at the castration-resistant stage, thus suggesting a vital role of PrLZ in the progression of CRPC. In this study, we aimed to investigate the role of PrLZ in docetaxel resistance in PCa, focusing on PrLZ-regulating autophagy pathway.
METHODS: Human PCa PC3, LNCaP and C4-2 cell lines were used as the model system in vitro and PCa xenografts and PrLZknockout mice were used as the model system in vivo. Docetaxelinduced cell death and apoptosis in PCa were determined by MTT and flow cytometry assay. The effects of PrLZ on autophagy were determined by LC3 conversion, LC3 turnover, and LC3-GFP-RFP puncta assay. The role of PrLZ in the regulation of autophagy and liver kinase e1228 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 
